Literature DB >> 2572822

Intralesional vinblastine for oral Kaposi sarcoma in HIV infection.

J B Epstein, C Scully.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2572822     DOI： 10.1016/s0140-6736(89)91114-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Oral shedding of herpesviruses in HIV-infected patients with varying degrees of immune status.

Authors:  Dirk P Dittmer; Kristen Tamburro; Huichao Chen; Anthony Lee; Marcia K Sanders; Tischan A Wade; Sonia Napravnik; Jennifer Webster-Cyriaque; Mahmoud Ghannoum; Caroline H Shiboski; Judith A Aberg
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

2.  Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells.

Authors:  J Corbeil; E Rapaport; D D Richman; D J Looney
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

3.  Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation.

Authors:  Hiroaki Tanaka; Hironori Matsushima; Akiko Nishibu; Björn E Clausen; Akira Takashima
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

Review 4.  Treatment of Kaposi's sarcoma. Current guidelines and future perspectives.

Authors:  D W Northfelt
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.